Zheng, Rui Chen, Yuankun Zhang, Yiting Liang, Sixin Zhao, Xiaojuan Wang, Yiyi Wang, Pengju Meng, Ruotong Yang, Angang Yan, Bo
...
Published in
Frontiers in Immunology
Introduction Chimeric antigen receptors (CARs) can redirect T cells against antigen-expressing tumors, and each component plays an important role in the function and anti-tumor efficacy. It has been reported that using human sequences or a low affinity of CAR single-chain variable fragments (scFvs) in the CAR binding domains is a potential way to e...
Burger, Michael C Forster, Marie-Therese Romanski, Annette Straßheimer, Florian Macas, Jadranka Zeiner, Pia S Steidl, Eike Herkt, Stefanie Weber, Katharina J Schupp, Jonathan
...
Published in
Neuro-oncology
Glioblastoma (GB) is incurable at present without established treatment options for recurrent disease. In this phase I first-in-human clinical trial we investigated safety and feasibility of adoptive transfer of clonal chimeric antigen receptor (CAR)-NK cells (NK-92/5.28.z) targeting HER2, which is expressed at elevated levels by a subset of gliobl...
Najafi, Ahmad Valadan, Reza Asgarian-Omran, Hossein Rafiei, Alireza Tehrani, Mohsen
Published in
International immunopharmacology
Dimer-dependent phosphorylation of HER2 receptor is a key event for the signal transduction of HER family of receptors which correlates with tumor invasion and metastasis. New generation of therapies based on dimerization domain inhibition using monoclonal or fragment antibodies was introduced. A potent method for manufacturing antibodies and antib...
Liu, Xinlin Luan, Linli Liu, Xi Jiang, Dingwen Deng, Junwen Xu, Jiazhen Yuan, Yang Xing, Jiyao Chen, Bingguan Xing, Dongming
...
Published in
Frontiers in Immunology
Human epithelial growth factor receptor-2 (HER2) plays an oncogenic role in numerous tumors, including breast, gastric, and various other solid tumors. While anti-HER2 therapies are approved for the treatment of HER2-positive tumors, a necessity persists for creating novel HER2-targeted agents to resolve therapeutic resistance. Utilizing a syntheti...
Debets, Donna O Stecker, Kelly E Piskopou, Anastasia Liefaard, Marte C Wesseling, Jelle Sonke, Gabe S Lips, Esther H Altelaar, Maarten
Published in
Cell reports. Medicine
Patients with early-stage HER2-overexpressing breast cancer struggle with treatment resistance in 20%-40% of cases. More information is needed to predict HER2 therapy response and resistance in vivo. In this study, we perform (phospho)proteomics analysis of pre-treatment HER2+ needle biopsies of early-stage invasive breast cancer to identify molecu...
Tintelnot, Joseph Stein, Alexander Al-Batran, Salah-Eddin Ettrich, Thomas Götze, Thorsten Grün, Barbara Haag, Georg Martin Heuer, Vera Hofheinz, Ralf-Dieter Homann, Nils
...
Published in
Frontiers in Oncology
Background Esophagogastric adenocarcinoma (EGA) presents a substantial global health challenge as the number of cases continues to rise. The current standard approach for treating localized EGA involves a combination of triplet chemotherapy, which consists of a platinum compound, a fluoropyrimidine, and a taxane (known as FLOT), followed by surgery...
Zheng, Yue Xue, Yin-Yin Zhao, Ya-Qin Chen, Ye Li, Zhi-Ping
Published in
Frontiers in Immunology
Primary urethral carcinoma (PUC) has a low incidence, but with high aggressiveness. Most of the patients are found in late stage, with poor prognosis. At present, chemotherapy is still the main treatment for metastatic PUC, but it has limited effect. Here, we report a case of metastatic PUC with low HER2 expression that developed disease progressio...
Lee, Jiyun Park, Sehhoon Jung, Hyun Ae Lee, Se-Hoon Seo, Seyoung Kim, Sung-Bae Kim, Ji-Won Lee, Keun-Wook Kang, Eun Joo Kim, Ju Won
...
Published in
Cancer
Salivary duct carcinoma (SDC) is uncommon but is the most aggressive subtype of salivary gland carcinomas. The high positivity rate for human epidermal growth factor receptor 2 (HER2) led to an investigation of the efficacy of HER2-targeted agents. Docetaxel-PM (polymeric micelle) is a low-molecular-weight, nontoxic, biodegradable, and docetaxel-lo...
Byrd, Brook K Wells, Wendy A Strawbridge, Rendall R Barth, Connor W Samkoe, Kimberley S Gibbs, Summer L Davis, Scott C
Published in
Molecular imaging and biology
Reliable and rapid identification of tumor in the margins of breast specimens during breast-conserving surgery to reduce repeat surgery rates is an active area of investigation. Dual-stain difference imaging (DDSI) is one of many approaches under evaluation for this application. This technique aims to topically apply fluorescent stain pairs (one ta...
Kondo, Misaki Cai, Zhongli Chan, Conrad Forkan, Nubaira Reilly, Raymond M
Published in
EJNMMI radiopharmacy and chemistry
Trastuzumab (Herceptin) has improved the outcome for patients with HER2-positive breast cancer (BC) but brain metastases (BM) remain a challenge due to poor uptake of trastuzumab into the brain. Radioimmunotherapy (RIT) with trastuzumab labeled with α-particle emitting, 225Ac may overcome this challenge by increasing the cytotoxic potency on HER2-p...
